Advertisement

Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction – The SITAGRAMI-miR analysis

  • U. Grabmaier
    Affiliations
    Department of Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany

    DZHK (German Centre for Cardiovascular Research), Partner Site Munich, Munich Heart Alliance (MHA), Munich, Germany
    Search for articles by this author
  • S. Clauss
    Affiliations
    Department of Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany

    DZHK (German Centre for Cardiovascular Research), Partner Site Munich, Munich Heart Alliance (MHA), Munich, Germany
    Search for articles by this author
  • L. Gross
    Affiliations
    Department of Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany

    DZHK (German Centre for Cardiovascular Research), Partner Site Munich, Munich Heart Alliance (MHA), Munich, Germany
    Search for articles by this author
  • I. Klier
    Affiliations
    Department of Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany
    Search for articles by this author
  • W.M. Franz
    Affiliations
    Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria
    Search for articles by this author
  • G. Steinbeck
    Affiliations
    Department of Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany
    Search for articles by this author
  • R. Wakili
    Affiliations
    Department of Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany

    DZHK (German Centre for Cardiovascular Research), Partner Site Munich, Munich Heart Alliance (MHA), Munich, Germany
    Search for articles by this author
  • H.D. Theiss
    Affiliations
    Department of Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany
    Search for articles by this author
  • C. Brenner
    Correspondence
    Corresponding author at: Department of Cardiology and Angiology, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria.
    Affiliations
    Department of Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany

    Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria

    Department of Cardiology, REHA Zentrum Muenster, Tyrol, Austria
    Search for articles by this author

      Abstract

      Background

      MicroRNAs (miRs) have shown to exert fibrotic and anti-fibrotic effects in preclinical models of acute myocardial infarction (AMI). The aim of this study was to evaluate miR-1, miR-21, miR-29b and miR-92a as circulating biomarkers for adverse ventricular remodeling (AVR) in post-AMI patients.

      Methods

      Plasma levels of miR-1, miR-21, miR-29b and miR-92a were measured in 44 patients of the SITAGRAMI trial population at day 4, day 9 and 6 month after AMI and in 18 matched controls (CTL). MiR expression patterns were correlated with magnetic resonance imaging (MRI) parameters for AVR (absolute change (Δ) in infarct volume (IV), left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume (LVEDV) between day 4 and 6 months after AMI) and a combined cardiovascular endpoint.

      Results

      Expression of miR-1, miR-21 and miR-29b but not miR-92a was increased in AMI vs. CTL cohort showing highest miR levels at d9. However, only miR-1 and miR-29b levels significantly correlated with ΔIV and showed a trend for correlation with ΔLVEF. Only miR-29b levels at day 9 correlated with ΔLVEDV at 6-month follow-up. There was no correlation of miR levels with an adverse outcome.

      Conclusion

      Mir-1 and miR-29b plasma levels post-AMI correlate with IV changes. In addition, miR-29b levels are associated with changes of LVEDV over time. These results provide insights into the role of miRs as diagnostic AVR surrogate markers. Further large scale clinical trials will be needed to evaluate the real prognostic relevance of these miRs with respect to a clinical implication in the future.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Laflamme M.A.
        • Murry C.E.
        Regenerating the heart.
        Nat. Biotechnol. 2005; 23: 845-856
        • Talman V.
        • Ruskoaho H.
        Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration.
        Cell Tissue Res. 2016;
        • Xu C.
        • Lu Y.
        • Pan Z.
        • Chu W.
        • Luo X.
        • Lin H.
        • et al.
        The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes.
        J. Cell Sci. 2007; 120: 3045-3052
        • Shan Z.X.
        • Lin Q.X.
        • Fu Y.H.
        • Deng C.Y.
        • Zhou Z.L.
        • Zhu J.N.
        • et al.
        Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction.
        Biochem. Biophys. Res. Commun. 2009; 381: 597-601
        • Zile M.R.
        • Mehurg S.M.
        • Arroyo J.E.
        • Stroud R.E.
        • DeSantis S.M.
        • Spinale F.G.
        Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction.
        Circ. Cardiovasc. Genet. 2011; 4: 614-619
        • Cheng Y.
        • Tan N.
        • Yang J.
        • Liu X.
        • Cao X.
        • He P.
        • et al.
        A translational study of circulating cell-free microRNA-1 in acute myocardial infarction.
        Clin. Sci. (Lond.). 2010; 119: 87-95
        • Ai J.
        • Zhang R.
        • Li Y.
        • Pu J.
        • Lu Y.
        • Jiao J.
        • et al.
        Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction.
        Biochem. Biophys. Res. Commun. 2010; 391: 73-77
        • Kuwabara Y.
        • Ono K.
        • Horie T.
        • Nishi H.
        • Nagao K.
        • Kinoshita M.
        • et al.
        Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage.
        Circ. Cardiovasc. Genet. 2011; 4: 446-454
        • Thum T.
        • Gross C.
        • Fiedler J.
        • Fischer T.
        • Kissler S.
        • Bussen M.
        • et al.
        MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts.
        Nature. 2008; 456: 980-984
        • Patrick D.M.
        • Montgomery R.L.
        • Qi X.
        • Obad S.
        • Kauppinen S.
        • Hill J.A.
        • et al.
        Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice.
        J. Clin. Invest. 2010; 120: 3912-3916
        • Roy S.
        • Khanna S.
        • Hussain S.R.
        • Biswas S.
        • Azad A.
        • Rink C.
        • et al.
        MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue.
        Cardiovasc. Res. 2009; 82: 21-29
        • Dong S.
        • Cheng Y.
        • Yang J.
        • Li J.
        • Liu X.
        • Wang X.
        • et al.
        MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction.
        J. Biol. Chem. 2009; 284: 29514-29525
        • van Rooij E.
        • Sutherland L.B.
        • Thatcher J.E.
        • DiMaio J.M.
        • Naseem R.H.
        • Marshall W.S.
        • et al.
        Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis.
        Proc. Natl. Acad. Sci. U. S. A. 2008; 105: 13027-13032
        • Zhang Y.
        • Huang X.R.
        • Wei L.H.
        • Chung A.C.
        • Yu C.M.
        • Lan H.Y.
        miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling.
        Mol. Ther. 2014; 22: 974-985
        • Zhu J.N.
        • Chen R.
        • Fu Y.H.
        • Lin Q.X.
        • Huang S.
        • Guo L.L.
        • et al.
        Smad3 inactivation and MiR-29b upregulation mediate the effect of carvedilol on attenuating the acute myocardium infarction-induced myocardial fibrosis in rat.
        PLoS One. 2013; 8e75557
        • Dawson K.
        • Wakili R.
        • Ordog B.
        • Clauss S.
        • Chen Y.
        • Iwasaki Y.
        • et al.
        MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation.
        Circulation. 2013; 127 (75e1-28): 1466-1475
        • Hinkel R.
        • Penzkofer D.
        • Zuhlke S.
        • Fischer A.
        • Husada W.
        • Xu Q.F.
        • et al.
        Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model.
        Circulation. 2013; 128: 1066-1075
        • Zhang Y.
        • Cheng J.
        • Chen F.
        • Wu C.
        • Zhang J.
        • Ren X.
        • et al.
        Circulating endothelial microparticles and miR-92a in acute myocardial infarction.
        Biosci. Rep. 2017;
        • Brenner C.
        • Adrion C.
        • Grabmaier U.
        • Theisen D.
        • von Ziegler F.
        • Leber A.
        • et al.
        Sitagliptin plus granulocyte colony-stimulating factor in patients suffering from acute myocardial infarction: a double-blind, randomized placebo-controlled trial of efficacy and safety (SITAGRAMI trial).
        Int. J. Cardiol. 2016; 205: 23-30
        • Gross L.
        • Theiss H.D.
        • Grabmaier U.
        • Adrion C.
        • Mansmann U.
        • Sohn H.Y.
        • et al.
        Combined therapy with sitagliptin plus granulocyte-colony stimulating factor in patients with acute myocardial infarction - long-term results of the SITAGRAMI trial.
        Int. J. Cardiol. 2016; 215: 441-445
        • Theiss H.D.
        • Brenner C.
        • Engelmann M.G.
        • Zaruba M.M.
        • Huber B.
        • Henschel V.
        • et al.
        Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from acute myocardial infarction (SITAGRAMI-trial)--rationale, design and first interim analysis.
        Int. J. Cardiol. 2010; 145: 282-284
        • Glinge C.
        • Clauss S.
        • Boddum K.
        • Jabbari R.
        • Jabbari J.
        • Risgaard B.
        • et al.
        Stability of circulating blood-based MicroRNAs - pre-analytic methodological considerations.
        PLoS One. 2017; 12e0167969
        • Clauss S.
        • Wakili R.
        • Hildebrand B.
        • Kaab S.
        • Hoster E.
        • Klier I.
        • et al.
        MicroRNAs as biomarkers for acute atrial remodeling in marathon runners (the miRathon study—a sub-study of the Munich Marathon study).
        PLoS One. 2016; 11e0148599
        • D'Alessandra Y.
        • Devanna P.
        • Limana F.
        • Straino S.
        • Di Carlo A.
        • Brambilla P.G.
        • et al.
        Circulating microRNAs are new and sensitive biomarkers of myocardial infarction.
        Eur. Heart J. 2010; 31: 2765-2773
        • Wang G.K.
        • Zhu J.Q.
        • Zhang J.T.
        • Li Q.
        • Li Y.
        • He J.
        • et al.
        Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans.
        Eur. Heart J. 2010; 31: 659-666
        • Liu X.
        • Dong Y.
        • Chen S.
        • Zhang G.
        • Zhang M.
        • Gong Y.
        • et al.
        Circulating microRNA-146a and microRNA-21 predict left ventricular remodeling after ST-elevation myocardial infarction.
        Cardiology. 2015; 132: 233-241

      Linked Article